Literature DB >> 21671081

Familial colorectal cancer: eleven years of data from a registry program in Switzerland.

Michal Kovac1, Endre Laczko, Ritva Haider, Josef Jiricny, Hansjakob Mueller, Karl Heinimann, Giancarlo Marra.   

Abstract

Deleterious germ-line variants involving the DNA mismatch repair (MMR) genes have been identified as the cause of the hereditary nonpolyposis colorectal cancer syndrome known as the Lynch syndrome, but in numerous familial clusters of colon cancer, the cause remains obscure. We analyzed data for 235 German-speaking Swiss families with nonpolyposis forms of colorectal cancer (one of the largest and most ethnically homogeneous cohorts of its kind) to identify the phenotypic features of forms that cannot be explained by MMR deficiency. Based on the results of microsatellite instability analysis and immunostaining of proband tumor samples, the kindreds were classified as MMR-proficient (n = 134, 57%) or MMR-deficient (n = 101, 43%). In 81 of the latter kindreds, deleterious germ-line MMR-gene variants have already been found (62 different variants, including 13 that have not been previously reported), confirming the diagnosis of Lynch syndrome. Compared with MMR-deficient kindreds, the 134 who were MMR proficient were less likely to meet the Amsterdam Criteria II regarding autosomal dominant transmission. They also had primary cancers with later onset and colon-segment distribution patterns resembling those of sporadic colorectal cancers, and they had lower frequencies of metachronous colorectal cancers and extracolonic cancers in general. Although the predisposition to colorectal cancer in these kindreds is probably etiologically heterogeneous, we were unable to identify distinct phenotypic subgroups solely on the basis of the clinical data collected in this study. Further insight, however, is expected to emerge from the molecular characterization of their tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671081     DOI: 10.1007/s10689-011-9458-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  30 in total

1.  Multiple colorectal adenomas--is their number up?

Authors:  Giancarlo Marra; Josef Jiricny
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

2.  Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status.

Authors:  Laura Valle; Jose Perea; Pablo Carbonell; Victoria Fernandez; Ana M Dotor; Javier Benitez; Miguel Urioste
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

5.  Defective DNA mismatch repair determines a characteristic transcriptional profile in proximal colon cancers.

Authors:  Massimiliano di Pietro; Jacob Sabates Bellver; Mirco Menigatti; Fridolin Bannwart; Annelies Schnider; Anna Russell; Kaspar Truninger; Josef Jiricny; Giancarlo Marra
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

6.  Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway.

Authors:  Xavier Llor; Elisenda Pons; Rosa M Xicola; Antoni Castells; Cristina Alenda; Virgínia Piñol; Montserrat Andreu; Sergi Castellví-Bel; Artemio Payá; Rodrigo Jover; Xavier Bessa; Anna Girós; Anna Roca; Miquel A Gassull
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

7.  Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer.

Authors:  Elise Renkonen; Yange Zhang; Hannes Lohi; Reijo Salovaara; Wael M Abdel-Rahman; Mef Nilbert; Kristiina Aittomaki; Heikki J Jarvinen; Jukka-Pekka Mecklin; Annika Lindblom; Paivi Peltomaki
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

8.  Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer.

Authors:  J R Jass; D S Cottier; P Jeevaratnam; V Pokos; K M Holdaway; M L Bowden; N S Van de Water; P J Browett
Journal:  Lancet       Date:  1995-11-04       Impact factor: 79.321

Review 9.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

10.  A new variant database for mismatch repair genes associated with Lynch syndrome.

Authors:  Michael O Woods; Phillip Williams; Amanda Careen; Laura Edwards; Sylvia Bartlett; John R McLaughlin; H Banfield Younghusband
Journal:  Hum Mutat       Date:  2007-07       Impact factor: 4.878

View more
  2 in total

1.  Mutation Spectrum of Cancer-Associated Genes in Patients With Early Onset of Colorectal Cancer.

Authors:  Gulnur Zhunussova; Georgiy Afonin; Saltanat Abdikerim; Abai Jumanov; Anastassiya Perfilyeva; Dilyara Kaidarova; Leyla Djansugurova
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

2.  Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation.

Authors:  Manuela Pinheiro; Carla Pinto; Ana Peixoto; Isabel Veiga; Paula Lopes; Rui Henrique; Helena Baldaia; Fátima Carneiro; Raquel Seruca; Ian Tomlinson; Michal Kovac; Karl Heinimann; Manuel R Teixeira
Journal:  Br J Cancer       Date:  2015-08-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.